Company Shares of Hologic Drops by -0.97%

Hologic (NASDAQ:HOLX) has tumbled 0.97% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.41% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 0.22% and the outperformance has advanced to 0.48% for the last 4 weeks period.

Hologic (NASDAQ:HOLX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $33.58 and $33.33 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $33.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $33.81, notching a gain of 0.33% for the day. The total traded volume was 4,982,381 . The stock had closed at $33.70 on the previous day.

The company shares have dropped -11.63% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $43.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $33.91 and the 200 Day Moving Average price is recorded at $35.49.

On the companys insider trading activities,The director of Hologic Inc, Levy Lawrence M sold 17,794 shares at $34.41 on June 1, 2016. The Insider selling transaction had a total value worth of $612,292. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Needham, downgrades their rating on the shares of Hologic (NASDAQ:HOLX). Needham has a Hold rating on the shares. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on April 28, 2016. Currently the company Insiders own 0.84% of Hologic shares according to the proxy statements. Institutional Investors own 91.97% of Hologic shares.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Leave a Reply

oliver - Is it time to Sell?

Top Brokerage Firms are advising their investors on oliver. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.